Skip to content

All Press Releases

PILA PHARMA ANNOUNCES PROGRESSION AND CO-SPONSORSHIP OF PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE

Malmö, 13 November 2024 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the co-sponsorship of the research collaboration with the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (the "Research Group") to complete initial investigations on the effect of PILA PHARMA's lead molecule, XEN-D0501, on Abdominal Aorta Aneurism growth in mice. The hypothesis is that XEN-D0501 may…

Read more

PILA PHARMA INFORMS OF OPTIMIZATION CHANGES TO TRIAL PLAN

Malmö, 17 October 2024 PILA PHARMA AB (publ) (FN STO:PILA) today announces it has chosen to alter the operational plan for its next clinical trial, PP-CT03, a phase 2a safety and tolerability trial in people living with obesity and type 2 diabetes.  On 25 July, PILA PHARMA entered into agreement with a UK based clinical research organisation on supply of…

Read more

CEO Gustav H. Gram increases holding in PILA PHARMA AB

Malmö, 02 September 2024 Pila Pharma AB (publ) (FN STO: PILA) announces that recently appointed CEO Gustav H. Gram has purchased additional shares. The purchases occurred on Wednesday, 30 August, where 29.375 shares in the company were acquired. The shares were purchased at an average price of SEK 5,1768.___Mr. Gram's direct holdings in Pila Pharma AB now amounts to 74.816 shares.CEO Gustav H…

Read more

Contact us

Subscription for press releases
Back To Top